| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
Pregnanediol (NSC 1612; NSC 47462; 5β-pregnane-3α,20α-diol), an inactive metabolic product of progesterone, can be formed when the body breaks down the hormone progesterone. A test can be done to measure the amount of pregnanediol in urine, which offers an indirect way to measure progesterone levels in the body. Pregnanediol will be transformed in to Pregnanediol-3-Glucuronide (5β-pregnane-3α,20α-diol-3α-glucuronide, PDG or P3G) eventually.
| ADME/Pharmacokinetics |
Pregnanediol (PD) is the main metabolite of progesterone and is primarily excreted in urine. Men excrete approximately 1 mg of PD daily, while pregnant women excrete up to 70 mg. Approximately 15% of progesterone is excreted as PD. [1]
|
|---|---|
| Toxicity/Toxicokinetics |
No significant effects were observed when zebrafish embryos were exposed to environmental concentrations of pregnanediol (PD) (and other steroids). In contrast, a mixture of simulated wastewater and river water components affected zebrafish embryo development and led to alterations in gene expression. [1]
|
| References | |
| Additional Infomation |
Pregnanediol is a corticosteroid hormone and a tautomer of 5β-pregnane-3β,20α-diol. It is an inactive metabolite produced by the reduction of progesterone at the C5, C3, and C20 positions. Pregnanediol has two hydroxyl groups, located at the 3α and 20α positions, respectively. Pregnanediol can be detected in urine after ovulation, and its concentration is higher during pregnancy. Pregnanediol (PD) is the main metabolite of progesterone. This study developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for trace analysis of pregnanediol and 32 other steroids in environmental water samples (river water, wastewater treatment plant influent and effluent). The method employs solid-phase extraction, and the washing and elution steps were optimized to reduce matrix effects, followed by HPLC-MS/MS multiple reaction monitoring (MRM) analysis. The method showed good sensitivity, with a detection limit (MDL) of 3 ng/L in river water, 10 ng/L in wastewater treatment plant effluent, and 40 ng/L in wastewater treatment plant influent. The recovery rate of PD in different sample matrices ranged from 92% to 106%. The method was applied to environmental samples in Switzerland, and PD concentrations as high as 400 ng/L were detected in wastewater treatment plant influent, but no PD concentrations exceeding the detection limit were detected in effluent or river water. The study indicated that PD is an endogenous steroid metabolite, and its presence in the environment is related to human and animal excretion. [1]
|
| Molecular Formula |
C21H36O2
|
|---|---|
| Molecular Weight |
320.5093
|
| Exact Mass |
320.272
|
| CAS # |
80-92-2
|
| PubChem CID |
219833
|
| Appearance |
White to off-white solid powder
|
| Density |
1.053g/cm3
|
| Boiling Point |
435.9ºC at 760 mmHg
|
| Melting Point |
240-242ºC
|
| Flash Point |
191ºC
|
| Index of Refraction |
1.531
|
| LogP |
4.387
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C)O
|
| InChi Key |
YWYQTGBBEZQBGO-BERLURQNSA-N
|
| InChi Code |
InChI=1S/C21H36O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h13-19,22-23H,4-12H2,1-3H3/t13-,14+,15+,16-,17+,18-,19-,20-,21+/m0/s1
|
| Chemical Name |
(3R,5R,8R,9S,10S,13S,14S,17S)-17-[(1S)-1-hydroxyethyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
NSC 1612; NSC 47462; NSC-1612; NSC-47462; NSC1612; NSC47462;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~5 mg/mL (~15.60 mM)
DMSO : ~2 mg/mL (~6.24 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.56 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.56 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1200 mL | 15.6001 mL | 31.2003 mL | |
| 5 mM | 0.6240 mL | 3.1200 mL | 6.2401 mL | |
| 10 mM | 0.3120 mL | 1.5600 mL | 3.1200 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA